Where each interaction happens is the organizing idea of this interaction review for MN553 Unit 7, which sorts three planted problems by mechanism and adds one the prompt missed. Searches like "mn 553 unit 7 assignment example", "mn553 unit 7 sample" and "mn553 unit 7 example" land here.
Twelve Medicines, Four Prescribers: A Drug Interaction Review for a 71-Year-Old Retired Pipefitter
[Student Name]
Purdue University Global
MN553: Advanced Pharmacology
Unit 7 Assignment
[Instructor Name]
[Date]
Composite patient and medication list written as a model document. No real patient or prescriber is described, and nothing here is a prescribing instruction.
Medication Table
A composite 71-year-old retired pipefitter with coronary artery disease, hypertension, rosacea, erectile dysfunction, gastroesophageal reflux and osteoarthritis brings all his medicine bottles to a primary care review on September 22, 2026. Prescribers: primary care (PC), cardiology (C), urology (U), dermatology (D), urgent care (UC) and over the counter (OTC).
1. Simvastatin 40 mg nightly, hyperlipidemia, C, since 2019. Interacts (Findings 1 and 4).
2. Amlodipine 10 mg daily, hypertension and angina, C, since 2021. Interacts (Finding 4).
3. Isosorbide mononitrate extended-release 60 mg daily, angina, C, since 2022. Interacts (Finding 2).
4. Metoprolol succinate 50 mg daily, coronary disease, C, since 2019.
5. Aspirin 81 mg daily, coronary disease, C, since 2019.
6. Clopidogrel 75 mg daily, coronary stent, C, since March 2026.
7. Lisinopril 10 mg daily, hypertension, PC, since 2017.
8. Sildenafil 50 mg as needed, erectile dysfunction, U, since June 2026. Interacts (Finding 2).
9. Doxycycline 40 mg modified-release daily, rosacea, D, since August 2026. Interacts (Finding 3).
10. Calcium carbonate 1,000 mg with breakfast, heartburn, OTC, for years. Interacts (Finding 3).
11. Clarithromycin 500 mg twice daily for 7 days, sinusitis, UC, started 4 days ago. Interacts (Finding 1).
12. Acetaminophen 650 mg up to three times daily, knee pain, OTC.
Finding 1 (Liver): Clarithromycin With Simvastatin
Mechanism: Simvastatin is extensively metabolized by cytochrome P450 3A4 (CYP3A4) in the gut wall and liver, which keeps its systemic exposure low. Clarithromycin is a strong CYP3A4 inhibitor. When the enzyme is blocked, simvastatin and its active acid form accumulate, and exposure can rise many times over (Wiggins et al., 2016).
Consequence for him: Statin-associated myopathy, and rarely rhabdomyolysis with kidney injury, is dose- and exposure-dependent. Four days into a seven-day course, with simvastatin at 40 mg and amlodipine already raising its exposure (Finding 4), he is in the period of highest risk now. He should be asked today about muscle pain, weakness or dark urine.
Why the statin matters: The risk is greatest with simvastatin and lovastatin, which depend most on CYP3A4, and small with pravastatin and rosuvastatin, which do not. The combination of clarithromycin with simvastatin is contraindicated in the product labeling.
Proposed change and owner: Primary care, as the reviewer, can act directly by asking him to hold simvastatin until three days after the last clarithromycin dose, and should notify urgent care and cardiology. An alternative antibiotic without CYP3A4 inhibition could also be considered, but holding the statin for a short course is simpler and carries little risk.
Finding 2 (Blood Vessel): Sildenafil With Isosorbide Mononitrate
Mechanism: Both drugs raise cyclic guanosine monophosphate (cGMP) in vascular smooth muscle by different routes. Isosorbide mononitrate releases nitric oxide, which activates guanylate cyclase and increases cGMP production. Sildenafil inhibits phosphodiesterase type 5, the enzyme that breaks cGMP down. One drug makes more of the messenger and the other stops it being cleared, so together they relax vascular smooth muscle far more than either would alone.
Consequence for him: The result can be a sudden, severe drop in blood pressure, with syncope, myocardial ischemia or worse in a man with coronary disease and a recent stent. This is a contraindication, not a monitoring issue.
Proposed change and owner: Primary care should contact both urology and cardiology rather than change either drug alone. Cardiology decides whether the nitrate is still needed; if it is, the sildenafil should be stopped and the patient told not to use it. He should be told today not to take sildenafil in the meantime, and why.
Finding 3 (Gut): Doxycycline With Calcium Carbonate
Mechanism: Tetracyclines, including doxycycline, form insoluble chelates with divalent and trivalent cations such as calcium, magnesium, aluminum and iron in the gut. Bound drug cannot be absorbed, and calcium-containing antacids can reduce tetracycline absorption substantially (Neuvonen, 1976). He takes both at breakfast, often within minutes of each other.
Consequence for him: Reduced doxycycline absorption may explain why his rosacea has not improved after six weeks. The effect is on efficacy, not safety.
Proposed change and owner: Primary care can advise separating the doses, taking doxycycline at least two hours before or several hours after the calcium carbonate, and should let dermatology know. The underlying heartburn, for which he takes calcium daily, is also worth reviewing.
Why These Problems Arose
None of the four findings came from a careless prescriber. Each drug was reasonable for the problem it was chosen to treat, and each prescriber saw only part of the list. Urgent care saw a sinus infection and a statin it may not have been told about. Urology saw erectile dysfunction in a man who may not have mentioned his cardiology medicines. Dermatology prescribed an antibiotic without knowing about a daily antacid bought over the counter. The amlodipine and simvastatin pairing predates the 2011 ceiling and was never revisited. The pattern is a risk in itself: four prescribers, one pharmacy for prescriptions and another store for over-the-counter products. The review therefore ends with two recommendations that are not about any single pair. First, he should carry one updated list, including over-the-counter products, to every appointment. Second, he should use one pharmacy for all prescriptions so that its interaction screening sees the whole list.
Pairs Checked and Cleared
The review checked every pair on the list. Aspirin with clopidogrel raises bleeding risk but is intended dual antiplatelet therapy after his stent in March. Metoprolol with amlodipine lowers heart rate and blood pressure together, which is intended for his angina. Lisinopril with metoprolol and amlodipine is a planned antihypertensive combination; his seated blood pressure today is 122/74 mm Hg. Acetaminophen at up to 1,950 mg daily is within limits and has no significant interactions on this list. Clopidogrel's activation depends on CYP2C19, not CYP3A4, so clarithromycin is not expected to reduce its effect meaningfully.
Finding 4, the One Nobody Planted: Amlodipine With Simvastatin
Mechanism: Amlodipine is a weak CYP3A4 inhibitor and raises simvastatin exposure. In 2011 the U.S. Food and Drug Administration set a ceiling of 20 mg daily for simvastatin when it is taken with amlodipine (U.S. Food and Drug Administration, 2011). He has taken simvastatin 40 mg with amlodipine 10 mg for five years.
Consequence and change: This is a chronic, lower-grade version of Finding 1 and adds to its risk this week. Cardiology, which prescribes both, should be asked to reduce simvastatin to 20 mg or switch to a statin that does not depend on CYP3A4, such as rosuvastatin or pravastatin, at an equivalent intensity. Planted problems are never the only ones on a real list, and this finding came from reading every line rather than searching for the three the prompt announced.
References
Neuvonen, P. J. (1976). Interactions with the absorption of tetracyclines. Drugs, 11(1), 45-54. https://doi.org/10.2165/00003495-197611010-00004
U.S. Food and Drug Administration. (2011). FDA drug safety communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor
Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016). Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 134(21), e468-e495. https://doi.org/10.1161/CIR.0000000000000456
How this MN553 Unit 7 example is structured
Findings are ordered by severity, not by list order, so the combination most likely to cause harm this week comes first. Every finding moves through four steps: the pair, the mechanism in one or two sentences, the likely consequence for this man, and the change proposed with who should make it. The statin finding identifies CYP3A4 and explains why the risk is greatest with simvastatin and lovastatin and small with pravastatin or rosuvastatin; the nitrate finding traces both drugs to cyclic GMP in vascular smooth muscle. The table marks every other pairing reviewed and dismissed, including two that look alarming but are intended, because a grader wants evidence the whole list was read. The unflagged fourth closes the paper with a sentence about why planted problems are never the only ones.
Get an MN553 Unit 7 example written to your instructions
Send the medication list from the MN553 Unit 7 case, its instructions and the grading rubric; lists of any length work. Back within 24-48h, the first sample free, comes a review that ranks each interaction by severity, names its mechanism and site, assigns every proposed change to the right prescriber, and shows the pairs it cleared. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN553 Unit 7 questions, answered
Should an interaction review rely on an interaction checker?
It can start there, but a checker's output is not the review. Checkers flag pairs and grade severity; they rarely explain mechanism or say what matters for a particular patient. Most instructors expect the mechanism stated in the student's own words, with the checker or a drug reference cited as the source for severity.
How many interactions is a review expected to find?
As many as the list actually holds. When a prompt says problems are planted, it usually means at least that many, and a careful read often finds another, such as a dose ceiling that applies only to one pairing. Reporting a pair checked and judged harmless also counts, because it shows the list was read in full.
Does the review need to say what to do about each interaction?
Most prompts ask for a recommendation, and a finding without one feels unfinished. The recommendation should fit the mechanism: separating doses for a binding problem, holding or switching for an enzyme problem, and contacting the prescriber for a contraindication. Any amount mentioned in the sample is bracketed, and the page supports coursework only; no actual medication list should be changed from it.